Based on our corporate philosophy of "contributing to the health of humankind through the development of revolutionary biotechnologies such as gene therapy," Takara Bio Group has positioned genetic engineering and cell engineering technologies as its core competencies, and while advancing the development of proprietary fundamental technologies, it has positioned the life sciences research support field and the health and medical-related industry support field as its business domains.
In May. 2023, We have formulated the Medium-Term Management Plan 2026. Under the New Medium-Term Management Plan, in order to overcome "the Corona Cliff"(The cliff of the business performance with or without the sales of the new Coronavirus testing-related products.) and achieve dramatic growth, we will reform our business structure, promote the sustainable growth of the Reagents/Instruments business and dramatic growth of CDMO business, and develop platform technology for biologics development.
We will also work to resolve social issues through highly unique business activities related to health, and take on the challenge of promote sustainability management with the aim of striking a balance between realization of a sustainable society and achieving sustainable growth of our group.
We will continue to create new value through proactive business activities, achieve sustainable growth, and contribute to society.
We deeply appreciate your ongoing support.
June 2024
Koichi Nakao
President
